Microbix Biosystems Inc. announced a collaboration with BioGX Inc. The companies are collaborating to make Microbix's Quality Assessment Products available to BioGX Xfree customers that perform tests on the portable BioGX pixl real-time PCR platform, and other systems such as the Applied Biosystems Quantstudio 5 and 7500 Fast Dx, the BD MAX, and the Bio-Rad CFX96 Touch and CFX384 Touch. Microbix was chosen by BioGX to be the primary External Quality Controls provider for assays on their newly-launched pixl platform - a benchtop instrument with capabilities for syndromic testing. To date, BioGX recommended nine PROCEEDxFLOQ QAPs to be used in conjunction with assays that detect a wide variety of infectious organisms, including but not limited to SARS-CoV-2 (COVID), Influenza A&B (Flu), Group A Streptococcus (Strep), Herpes Simplex Virus 1&2 (Herpes), Varicella Zoster Virus (Chicken Pox), Treponema pallidum (Syphilis), and Mpox virus (Monkeypox).

The tests can be shipped anywhere in the world without refrigeration, as can the QAPs. Microbix QAPs are now referenced in BioGX Assay Product Inserts, with additional QAPs to be referenced as the collaboration expands. Microbix?s current QAPs catalogue is available on its website.